An inferior vena cava (IVC) filter is a small cage-like medical device that can be inserted by doctors to stop dangerous blood clots from traveling to the blood vessels of the lungs. Their structure allows them to catch fragments of clots that form in the legs or pelvis before these blockages run the risk of causing a pulmonary embolism (PE). These metal filters are surgically implanted in patients who cannot tolerate blood thinners or have seen little success with those drugs.
Celebrex belongs to a special class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) called Cox-2 inhibitors.
Some of these types of drugs were noted to lead to an increased risk of stroke and heart attack. In fact, other NSAIDs were pulled from the market after these findings came to light.
Pfizer performed a study that involved doses of Celebrex up to twice as high as those recommended for rheumatoid arthritis patients. At those doses, cancer patients involved in the trial were experiencing "an approximately 2.5-fold increase in their risk of experiencing a major fatal or non-fatal cardiovascular event compared to those patients taking placebo," Pfizer said in a statement posted on its website.
However, Pfizer did not pull the drug off the market. The company says the study that found an increased risk of cardiovascular problems is not consistent with other studies Pfizer and other companies have accumulated over time.
In the wake of this evidence, many patients have felt that they were unreasonably put at risk by this drug company, and note made aware of these potentially dangerous results.
If you or a loved one experienced serious or fatal side effects while taking Celebrex, contact us today to determine if you may have a personal injury claim.